Role of Sp Proteins and RORalpha in Transcription Regulation of Murine Prosaposin*

Peng Jin, Ying Sun, and Gregory A. GrabowskiDagger

From the Division of Human Genetics, Children's Hospital Research Foundation, Children's Hospital Medical Center, Cincinnati, Ohio 45229-3039

    ABSTRACT
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Prosaposin is the precursor of four low molecular weight sphingolipid-activating proteins (SAPs) or saposins. These four proteins function as intracellular activators of several lysosomal enzymes involved in the degradation of glycosphingolipids, and prosaposin itself has neurite outgrowth effects. Expression of prosaposin is regulated in a temporal and spatial manner with expression in specific brain neurons and visceral cell types. Here a major regulatory fragment was characterized within 310 bp 5' to the transcription start site. Using electrophoretic mobility shift assay (EMSA) and DNA footprinting, members of the Sp family (Sp1, Sp3, and Sp4), the orphan nuclear receptor (RORalpha ), and an unknown transcription factor (U; TGGGGGAG) were shown to bind to this region. To evaluate the role of such transcription factor binding sites for this locus, a series of mutant constructs was generated within this region, and their function was evaluated in cultured NS20Y neuroblastoma cells. A 3' Sp1 site, a 5' Sp1/U cluster and the RORalpha binding sites were functional. The data are consistent with a model in which the factors that bind to the Sp1/U cluster and RORE site interact negatively to diminish promoter activity to a background level that is determined primarily by the 3' Sp1 site. These interactions depend on the tissue-specific repertoire of transcription factors leading to differential expression of this locus.

    INTRODUCTION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Prosaposin is a multifunctional protein with specific intra- and extracellular functions. It is the precursor of four 80-amino acid glycoprotein activators (1-4). In humans, rats, and mice the prosaposin mRNA encodes in tandem the highly similar saposins A, B, C, and D that participate in the sequential degradation of glycosphingolipids to sphingosine and fatty acids (2-5). In the rat, prosaposin is designated SGP-1, sulfated glycoprotein 1, since it is a major sulfated glycoprotein in Sertoli cells (5). In addition to prosaposin's essential role in glycosphingolipid degradation, it has ex vivo neurite outgrowth effects. When placed in the media surrounding neuroblastoma cells, prosaposin facilitates neurite outgrowth (6-8), and prosaposin facilitates in vivo regeneration of the sciatic nerve following injury (9). Prosaposin also functions in glycosphingolipid transfer between artificial membranes (10). Targeted disruption of the murine prosaposin gene resulted in a complex phenotype including severe central nervous system disease and widespread storage of multiple sphingolipids (11).

The human gene for prosaposin has been partially characterized to contain 13 (or 14) exons and 12 (or 13) introns (12, 13). An alternatively spliced 9-bp1 "exon" is present in the saposin B region of the prosaposin gene (12). The 13 (or 14) exons are spread over ~30 kb of human chromosome 10. Interestingly, the prosaposin gene, a presumed "housekeeping" gene, displays temporally and spatially regulated expression (14). Despite the ubiquitous role of lysosomal hydrolases in all tissue types, the level of prosaposin expression is highly dependent on the cell type and maturation. The highest levels of expression are in specific neurons of the adult cerebrum, the Purkinje cell layer of the cerebellum, and neurons of the lateral regions of the spinal cord (14). Components of the hind brain also show higher levels of mRNA expression early in embryogenesis (15).

Previously, we characterized the 5' region of the murine prosaposin gene including the first exon that contains the translation initiation site (16). The first intron of the mouse prosaposin locus is unusually large, almost 15 kb, and constitutes nearly 60% of the gene. Like many other housekeeping genes, the promoter region of the murine prosaposin gene is "TATA-less" and GC rich. The prosaposin gene has a major and a minor transcription start site. Transfection of deletion constructs containing reporter genes into NS20Y, NIH-3T3, or SF-7 (Sertoli) cells showed positive and negative regulatory elements within 2,400 bp 5' to the transcription start sites (16).

In this paper, we report the characterization of a major regulatory fragment located within 310 bp 5' to the murine prosaposin gene transcription start site. DNA footprinting, electrophoretic mobility shift assays (EMSA), and site-directed mutagenesis were used to analyze in vitro the interaction of transcription factors that bind to this fragment. Sp members 1, 3, and 4; RORalpha (the orphan nuclear receptor); and an unknown transcription factor (U) were identified to be involved in the regulation of the murine prosaposin gene. A complex interaction of multiple transcription factors is proposed to modulate gene expression from one essential Sp1 binding site within 16 bp 5' to the transcription start site.

    EXPERIMENTAL PROCEDURES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Materials-- The following materials were from commercial sources: WizardTM PCR Preps DNA kit, pGL2B Luciferase Reporter Vectors, the luciferase assay system, and the beta -galactosidase enzyme assay system (Promega, Madison, WI); restriction enzymes and Taq DNA polymerase (New England Biolabs, Beverly, MA); SequenaseTM version 2.0 DNA sequencing kit (U.S. Biochemical Corp.); oligonucleotide synthesis, poly(dI-dC), poly(dA-dT), NAP-10, and NAP-5 columns (Amersham Pharmacia Biotech); anti-Sp1, -Sp2, -Sp3, and -Sp4 antibodies (Santa Cruz Biotechnology, Inc., Santa Cruz, CA); QuickChange site-directed mutagenesis kit (Stratagene, La Jolla, CA); GeneClean Kit (BIO 101, Inc., Vista, CA); QIAGEN Plasmid Midi Kit (QIAGEN, Chatsworth, CA); Microcon microconcentrator 3 (Amicon, Inc, Beverly, MA); Lipofectamine, Opti-MEM serum-free medium, DMEM (Life Technologies, Inc.); Monolight 2010 luminometer (Analytical Luminescence Laboratory; San Diego, CA); isotope, [gamma -32P]ATP (NEN Life Science Products). Cell line NS20Y was from Dr. Marshall Nirenberg (National Institutes of Health).

Double-stranded Oligonucleotides-- Single-stranded oligonucleotides were synthesized on an Amersham Pharmacia Biotech DNA synthesizer. After purification with NAP-10 columns, the complementary oligonucleotides were heated at 95 °C for 5 min in the annealing buffer (20 mM Tris, pH 7.4, 2 mM MgCl2, and 50 mM NaCl) and then cooled to room temperature. The annealed oligonucleotides were purified by eletrophoresis in polyacrylamide gels.

Nuclear Extract Preparation-- Nuclear extracts were prepared using a miniextract procedure (17) with minor modifications. Nuclear extracts were desalted and concentrated using Microcon microconcentrator 3 (Amicon, Inc). Protein concentrations were estimated by the Bradford method (18).

EMSA-- The double-stranded oligonucleotides were labeled with [gamma -32P]ATP and T4 polynucleotide kinase. The probes were purified on NAP-5 columns. The labeled double-stranded oligonucleotides were incubated with 3-6 µg of nuclear extract at room temperature for 20 min in 20 µl containing 5% glycerol, 1 mM Mg Cl2, 0.5 mM dithiothreitol, 0.5 mM EDTA, 50 mM NaCl, 10 mM Tris-HCl (pH 7.5), and 0.5 mM fresh phenylmethylsulfonyl fluoride. Poly(dI-dC) or poly(dA-dT) was used as heterologous competitor in the reaction (800 ng/reaction). For antibody supershift assays, the extract was incubated overnight at 4 °C with the specific anti-Sp antibodies. Extract-antibody mixtures were then incubated with the probe. Bound and free probes were resolved by nondenaturing electrophoresis in 6% polyacrylamide gels.

DNase I Footprinting-- Polymerase chain reaction was used to generate 5'-end-labeled footprinting probes of the prosaposin promoter region (408 bp). A prosaposin deletion construct containing +98 bp to -310 bp was used as a template, and vector-specific (GLP1 and GLP2) primers were from Promega. The DNase I protection assays were performed with sense and antisense strands as described (19). The DNA binding reactions (50 µl) were done at 4 °C in 10 mM Tris, pH 7.5, 5 mM MgCl2, 50 µM EDTA, 75 mM KCl, 12% glycerol, 0.5 mM dithiothreitol, and 0.2 mM fresh phenylmethylsulfonyl fluoride. Bovine serum albumin (20 µg) without nuclear extract was used as a control. Nuclear extract (30 µg) or controls were first incubated with 1 µg of poly(dI-dC) for 15 min, and then 20,000 cpm of probe was added and incubated for 45 min. These reaction mixtures were subjected to DNase I digestion for 1 min at room temperature. The controls had 0.1 unit of DNase I/reaction while the nuclear extracts contained 0.4, 0.8, 1.2, or 1.6 units of DNase I/reaction. The DNA fragments were resolved by electrophoresis in 6% polyacrylamide, 7 M urea gels. The probe, cleaved at guanine and adenine with formic acid and piperidine (20), was used as a size marker.

Site-directed Mutagenesis-- Deletion constructs (16) were used as templates to create mutant constructs using the QuickChange site-directed mutagenesis kit (Stratagene). Briefly, site-directed mutations were generated by polymerase chain reaction using sense and antisense mutagenic oligonucleotide primers and Pfu DNA polymerase. The polymerase chain reaction product generated in this system was a nicked circular strand that was then digested with DpnI. The methylated, wild-type parental DNA template was digested, and the circular, nicked double-stranded DNA was transformed into XL2-Blue ultracompetent cells. Plasmid DNA from positive clones was digested with XhoI and HindIII and then recloned into the pGL2-basic vector. Each mutant construct was verified by DNA sequencing. The mutagenic oligonucleotide primers are listed in Table I. The primer pairs and templates used for each mutation construct are in Table II.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Primers for site-directed mutagenesis
Mutation sites are underlined.

                              
View this table:
[in this window]
[in a new window]
 
Table II
Templates and primer pairs for polymerase chain reaction mutagenesis of transcription factor binding sites

Transient Transfection and Reporter Gene Assays-- Functional assays of reporter constructs were performed using transient transfection of NS20Y cells (16). Confluent NS20Y cells were seeded at density of 105 cells/well into 12-well plates and incubated for 18 h at 37 °C. For each construct, 0.75 µg of test DNA and 0.25 µg of beta -galactosidase DNA were diluted into 50 µl of OPTI-MEM serum-free medium. This solution then was mixed with 4 µl of Lipofectamine in 50 µl of DMEM. The mixture was incubated at room temperature for 30 min to allow DNA-liposome complexes to form. The complexes were then mixed with 0.4 ml of DMEM and overlaid onto the DMEM-rinsed cells. After incubation for 5 h at 37 °C, the transfection mixtures were removed, and 1 ml of complete DMEM (with 10% fetal serum and 1% penicillin/streptomycin) was added to the cells. At 65 h after transfection, the cells were washed twice with phosphate-buffered saline by centrifugation (1000 × g, 5 min) and then incubated in the 200 µl of reporter lysis buffer (25 mM Tris-phosphate, pH 7.5, 2 mM EDTA, 2 mM dithiothreitol, 10% glycerol, 1% Triton X-100) at room temperature for 15 min with shaking. The cell lysate was collected, transferred into microcentrifuge tubes, vigorously agitated (15 s), and centrifuged (12,000 × g, 2 min). The supernatants were transferred to fresh tubes for luciferase and beta -galactosidase activity assays. For luciferase assays, lysate (20 µl) was mixed with luciferase assay reagent (100 µl). Light emission was quantified at room temperature. For the beta -galactosidase assay, lysate (10 µl) was diluted into lysis buffer (150 µl) and mixed with 150 µl of 2 × assay solution (120 mM Na2HPO4, 80 mM NaH2PO4, 2 mM MgCl2, 100 mM beta -mercaptoethanol, and 1.33 mg/ml O-nitrophenyl-beta -O-galactopyranoside). The mixture was incubated (37 °C, 20 min) and stopped with 1 M Na2CO3 (0.5 ml). The absorbance was determined at 420 nm. Luciferase activity was normalized to beta -galactosidase activity for each lysate collected from the individual transfection experiments. The results represent the means of three independent experiments conducted in triplicate.

    RESULTS
Top
Abstract
Introduction
Procedures
Results
Discussion
References

DNA Footprint Analysis-- A 408-bp segment (-310 to +98) from the 5' end of the murine prosaposin gene contained promoter activity in a number of different cell types (16). This promoter region is shown in Fig. 1 (GenBankTM accession number AF037437). Sequence analysis of the 310 bp 5' to the transcription start site revealed four potential Sp1 binding sites, three of which are overlapping in a 5' cluster, and GATA, AP-1, and RORalpha binding sites.


View larger version (28K):
[in this window]
[in a new window]
 
Fig. 1.   Partial DNA sequence of Exon 1 (in boldface type) and 5'-flanking regions of the mouse prosaposin gene. The numbering of nucleotides in the text is referenced to the major transcription start site (large arrow). The smaller arrow is a minor transcription start site (16). The translation initiation codon is boxed. Putative transcription factor binding sites, analyzed here, are underlined and labeled with appropriate consensus binding sequences.

DNA footprint analysis of this region (Fig. 2) showed three DNase I protected regions when using nuclear extracts from NS20Y cells and the sense probe. The control reactions contained bovine serum albumin. The most 3'-protected region (-32 to -12) is GC-rich and contains a Sp1 binding site. In particular, the AP-1 site did not footprint. A strongly protected region was at -184 to -164. This region has high homology to the RORalpha binding site (also termed ROR response element (RORE)) that is composed of a half-site PuGGTCA preceded by a 6-bp AT-rich region (21, 22). A weakly protected region was at -267 to -294 and contained three overlapping Sp1 binding sites. Using the antisense probe, similar results were obtained, but weaker protection was observed at the RORE and the 3' Sp1 binding sites (data not shown).


View larger version (82K):
[in this window]
[in a new window]
 
Fig. 2.   DNase I footprint analysis of the prosaposin promoter region shown in Fig. 1. The in vitro DNase I digestion pattern of the sense strand of the promoter region was in the presence of NS20Y nuclear extract or of bovine serum albumin (BSA). The triangle indicates an increasing amount of DNase I in the digestion. The G+A lane is the specific Gilbert sequencing reaction products for G and A. The boxes on the right indicate the regions protected from DNase I digestion by NS20Y cell nuclear extract. The filled rectangles are strongly protected regions. The hatched box was a region that was less strongly protected. Analyses were in -238 to +1 (A) and -213 to -300 (B).

EMSA-- To confirm the DNA footprinting results, EMSA was performed with several double-stranded oligonucleotides (Table III) that covered the protected regions. When EMSA was conducted with a probe (oligonucleotide 1, O1) covering bases -35 to -3, two major DNA-protein complexes were observed with NS20Y cell nuclear extracts (Fig. 3, A and B (lanes 1 and 2)). Formation of DNA-protein complexes was competed by an excess of unlabeled O1, but not by MO1, an oligonucleotide containing a mutated Sp1 binding site (Table III; Fig. 3B, lanes 3 and 4). The addition of excess cold Sp1 consensus oligonucleotide competed with labeled O1 for binding to the protein(s) (Fig. 3B, lane 5). When purified Sp1 protein was incubated with the same probe, a single DNA-protein complex was detected (Fig. 3B, lane 6). O3 was synthesized to cover three overlapping Sp1 binding sites from -298 to -263. Three DNA-protein complexes were resolved when this probe was incubated with NS20Y cell nuclear extracts (Fig. 3C, lanes 1 and 2). The formation of DNA-protein complexes was competed off by the addition of excess cold O3 (Fig. 3C, lane 3). However, excess Sp1 consensus oligonucleotides competed off only the slowest migrating DNA-protein complex. This indicated that other transcription factors also bind to this region and that their binding is independent of Sp1 binding (Fig. 3C, lane 4). The strong footprint from -184 to -164 covered a consensus RORalpha binding site (also termed RORE). However, there was a GATA binding site just 5 bp 3' to RORE. To determine which binding site was functional, we conducted EMSA with oligonucleotides 2 (O2) and 4 (O4) that cover the GATA binding site and RORE, respectively (Table III; Fig. 4A). No DNA-protein complexes were observed when O2 was incubated with NS20Y cell nuclear extract (Fig. 4B). Several DNA-protein complexes were detected with O4 and NS20Y nuclear extracts (Fig. 4C, lanes 1 and 2). The formation of these DNA-protein complexes was prevented by the addition of excess cold O4, but not MO4 (Fig. 4C, lanes 3 and 4). MO4 contains a mutated RORalpha binding site (Table III). These results indicate that RORE is functional but that the GATA binding site is not.

                              
View this table:
[in this window]
[in a new window]
 
Table III
Sequences of double-stranded oligonucleotides


View larger version (41K):
[in this window]
[in a new window]
 
Fig. 3.   EMSA with O1 (-35 to -3 bp) and O3 (-298 to -263 bp). Labeled oligonucleotides were incubated with NS20Y cell nuclear extract in the presence or absence of a 100-fold excess of unlabeled oligonucleotides. Poly(dI-dC) (800 ng) was added to each reaction. A, schematic diagram of the prosaposin sequences in Fig. 1 with three 5'-overlapping Sp1 and a U site in a cluster. The arrow represents the major transcription start site. The locations of O1 and O3 within this region are indicated by the underline. B, EMSA with O1. The legend above each lane indicates the contents of each reaction in addition to radiolabeled O1. The molar excess (100×) over the amount of radiolabeled O1 is indicated for cold O1, MO1 (a mutated O1 with destroyed Sp1 binding site), or Sp1 (a consensus Sp1). The arrows indicate the major shifted complexes. Lane 1 contains only radiolabeled O1. C, EMSA with O3. The legend above indicates the contents of the reactions in each lane in addition to radiolabeled O3. Lane 1 contains probe only. Lanes 2, 3, and 4 contain NS20Y nuclear extract. The arrows indicate DNA-protein complexes. F is the unbound probe.


View larger version (36K):
[in this window]
[in a new window]
 
Fig. 4.   EMSA with O2 (-168 to -133 bp) and O4 (-186 to -159 bp). Double-stranded labeled oligonucleotides were incubated with NS20Y nuclear extract in the presence or absence of 100-fold molar excess of unlabeled O2 or O4. Poly(dI-dC) (800 ng) was in each reaction. A, a schematic diagram of the nucleotide sequences in Fig. 1 with the locations of O2 and O4 underlined. B, EMSA with O2. Lane 1 contains probe only, and lane 2 contains the probe and NS20Y nuclear extract. C, EMSA with O4. Each lane contains radiolabeled probe, NS20Y nuclear extract, and the indicated additions. Lane 1, probe only; lane 2, no addition; lane 3, 100-fold excess unlabeled O4; lane 4, 100-fold excess unlabeled MO4. The MO4 has the RORE consensus site obliterated. The arrows indicate DNA-protein complexes. F, unbound probe.

The Sp1 multigene family includes Sp1 and three other genes encoding the Sp2, Sp3, and Sp4 proteins. The consensus binding sequences of these proteins are very similar (23, 24). No cross-reaction was detected among the antibodies for the individual Sp proteins, and none of them bound to O1 or O3 to form DNA-protein complexes (data not shown). Polyclonal antibodies against Sp1, Sp2, Sp3, or Sp4 were used for EMSA. Preincubation of anti-Sp1 or anti-Sp3 antibodies with NS20Y cell nuclear extracts produced a DNA-protein supershift using O1 and O3 (Fig. 5). A similar shift was obtained with Sp4 antibody using O1, but not with O3 (Fig. 5A, lane 6). For O1, the Sp1 and Sp3 antibodies appeared to supershift different bands and, by inference, interacted with different proteins or complexes. The Sp1 antibody supershifted a slower migrating band (lane 3), whereas the Sp3 antibody supershifted a faster migrating band (lane 5).


View larger version (38K):
[in this window]
[in a new window]
 
Fig. 5.   Gel supershift assays using anti-Sp antibodies. A, interaction of O1-protein complex with anti-Sp antibodies. Radiolabeled O1 was used as the probe. All lanes contain the radiolabeled probe. Lane 1, the radiolabeled O1 probe only; lanes 2-6, the probe and NS20Y nuclear extract plus the indicated additions; lane 2, no addition; lane 3, anti-Sp1 antibody; lane 4, anti-Sp2 antibody; lane 5, anti-Sp3 antibody; lane 6, anti-Sp4 antibody. B, interaction of O3-protein complexes with anti-Sp antibodies. Lane 1 contained only the radiolabeled O3. Lanes 2-6 contained the probe, NS20Y nuclear extract, and the indicated additions. Lane 2, no addition; lane 3, anti-Sp1 antibody; lane 4, anti-Sp2 antibody; lane 5, anti-Sp3 antibody; lane 6, anti-Sp4 antibody. The amount of antibody in each reaction is 0.5 µg. The whole reactions were incubated overnight at 4 °C. The complexes were resolved in 6% polyacrylamide gels. The arrows indicate the supershifts. The antibody added in each lane is indicated at the top of the gels. F, unbound probe.

Definition of an Unknown Transcription Factor Binding Site-- In the EMSA experiment using O3 as probe (Fig. 3C, lane 4), the addition of cold Sp1 consensus oligonucleotides eliminated the top band, but not the middle and bottom bands. This result shows that a transcription factor(s), in addition to Sp1, binds to this region and that this binding is independent of that for Sp1. In an attempt to define this transcription factor binding site, a series of mutant O3s were made to densely cover this region (Fig. 6A) and were used as probes during EMSA. NS20Y nuclear extracts were used. Three similar bands were obtained with the oligonucleotides 3, 3A-3D, and 3F. Oligonucleotide 3E produced only two supershifted bands, and one major band was missing, i.e. a transcription factor binds to the mutated region that was not covered in the oligonucleotide 3E region (Fig. 6B, lane 7). Competition assays using cold oligonucleotides 3A-3F against their radioactive derivatives showed that the bindings of each of the mutant O3s were specific (data not shown). A search of the transcription factor binding site data bases for the 3E region (TGGGGGAG) showed high homology to the myeloid zinc finger (MZF) protein consensus binding sequences (25). Cold MZF consensus oligonucleotides were synthesized and did not compete with labeled O3 for the formation DNA-protein complexes (data not shown). Thus, MZF is unlikely to bind to the region covered by O3. We defined this region as an unknown, or U, region (-270 to -277).


View larger version (79K):
[in this window]
[in a new window]
 
Fig. 6.   Definition of the U binding site using EMSA. A, the set of normal and mutant oligonucleotides used. B, EMSA with each mutant O3 as probe. The conditions were as in Fig. 3. Lane 1 contains radiolabeled O3 only. Lanes 2-8 contain nuclear extract and the radiolabeled O3 variants O3 and O3A-O3F in the respectively labeled lanes. Binding of each mutant O3 was shown to be specific by competition assays (data not shown). The arrows indicate DNA-protein complexes. F, unbound probe.

Mutational Analysis-- The function and potential interaction of the transcription factors that bind to the identified sites across this region were evaluated by mutagenesis and transfection/expression analyses (Fig. 7). For these studies, luciferase was used as the reporter gene, and NS20Y cells were transfected. Deletion constructs were made to contain -43, -114, -234, and -310 bp 5' and +98 bp 3' to the major transcription start site (+1). The constructs are arranged in groups to display the effects of the identified transcription factor binding sites up to the 5' Sp1/U cluster. The results with the first eight constructs show that destruction of the most 3' Sp1 site caused a >= 80% reduction in activity. Lengthening of the construct from -43 to -234 bp resulted in small (~15%) increases in absolute promoter activity until the RORE site was included (~45% increase). Destruction of the RORE alone reduced activity to nearly those observed with m114, whereas loss of the Sp1 site alone or together with RORE mutagenesis reduced activity to that observed with the m43m. These findings indicate that within the context of the m234 construct the 3' Sp1 is nearly essential for activity, and RORE adds an additional ~30% of activity. The sequences between the 5' end of the Sp1 site and -114 have minor, but consistent, positive effects, although this region did not footprint; nor are these known transcription factor binding sites in this region. Also, construct m310mC, which contains an additional 5' 76 bp and a destroyed 3' Sp1 site, gave promoter activity that was ~80% reduced relative to the wild-type sequence (m310) and about 45% of that for the shortest construct, m43. These results indicate the major importance of the most 3' Sp1 (designated D) site to the promoter of prosaposin.


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 7.   Mutagenesis of major transcriptionally active binding sites of the prosaposin promoter. Constructs refer to Table II where the designations and exact mutagenesis sequences are indicated and refer to the primers in Table I. The symbols refer to the designated transcription factor binding sites identified as participating in transcriptional modulation by DNA footprinting and/or EMSA (Figs. 2-6). The most 5' region represents three overlapping Sp1 consensus sequences, the most 3' of which overlaps the U (unknown) region. Together they constitute the Sp1/U cluster (Fig. 1). The Sp1 sites within m310 from 5' to 3' are labeled as A, B, C, and D. The open and closed symbols designate the wild-type and mutagenized sequences. The mutations obliterate the indicated binding sites. The horizontal lines represent sequences with identified (i.e. GATA or AP-1) or no identifiable transcription factor binding sites that are minor or nonfunctional by DNA footprinting, EMSA, or expression analysis. The mutagenized constructs are arranged in groups to highlight the effects of obliteration of the Sp1D site alone or in the presence or absence of wild-type or mutant RORE (first eight constructs) or the effects of systematic destruction of one or more of the 5' Sp1/cluster sites. This was with the RORE and Sp1D intact (seven constructs). The next five constructs underwent similar analyses as the previous seven but with the RORE site destroyed. The last eight constructs underwent similar analyses with Sp1D destroyed but with the RORE site intact (5 constructs) or destroyed (3 constructs). For each group, a promoter activity value of 100% was assigned for the wild-type sequence, and the absolute value is provided for the wild-type constructs for reference. All absolute values of luciferase activity were normalized to beta -galactosidase activity in lysates from individual co-transfection experiments. GL-2B and GL-2C are promoterless and SV40 promoter/enhancer-driven plasmid constructs, respectively, as negative and positive controls for the experiments.

The next series of constructs evaluated the effects of the 5' Sp1/U cluster in the context of intact 3' Sp1 and RORE. For clarity, the overlapping 5' Sp1 sites have been designed from 5' to 3' A, B, and C. Destruction of the Sp1 and U sites individually or in several combinations led to increased activity over the wild-type sequence (m310). The largest increases were found when site Sp1B and -C were destroyed alone (m310mA) or together with U (m310mD). Obliteration of Sp1A produced a small increase (m310mS), as did combinations of the Sp1A, -B, and -C mutagenesis with (m310mG) or without (m310mI) mutagenesis of U.

Similar analyses were conducted when the RORE site was mutated (m310mK backbone). Compared with wild-type sequence, the mutation of RORE enhanced activity, but the presence of additional mutations in the 5' Sp1/U cluster modulated the observed level and pattern of increased activity. Within the context of a mutant RORE, individual mutation of Sp1C with or without Sp1B or U mutagenesis (m310mO or P) in the cluster produced small decreases (20-50%) in activity. This contrasts with 90-160% increases in the context of a wild-type RORE. Destruction of the Sp1A, -B, and -C sites (m310mQ) produced a 90% increase in activity that was similar to that observed in the presence of a wild-type RORE site. The addition of a mutated U site (m310mR) produced the same level of activity as in a construct with an intact RORE (m310mI).

The final series of mutant constructs were made on the m310 backbone Sp1D destroyed. Compared with m310, this led to a substantial decrease in overall promoter activity (20-94%). Mutagenesis of all Sp1 sites and of the U and RORE sites (m310mM) gave absolute basal promoter activities that were very similar to those in m43m, m114m, and m234m3. Comparison of m310mC and m310mN shows a 3-fold increase in activity of m310mN that has a mutagenized RORE. Thus, the m310mN reflects the basal activity of the 5' Sp1/U cluster and that an intact RORE has a negative influence. The U region (m310mL) supports promoter activity at a level that is nearly equivalent to that observed with m114, i.e. with only Sp1D present. Taken in totality, these results support a promoter region within the first 310 bp 5' to the transcription start site that has complex, and mostly negative, interactions between elements. Each of these promoter elements alone has substantial ability to promote prosaposin expression and modulates basal promoter activity on the Sp1D background.

    DISCUSSION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

The multifunctional properties of prosaposin, its intracellular and extracellular functions, and the temporal and spatial regulation of its locus provided the rationale for the current studies to define the elements that facilitate expression of the prosaposin gene. Of lysosomal loci, prosaposin (14), lysosomal acid lipase (26), and acid alpha -glucosidase (27) have shown sufficient temporal and spatial variation in transcript levels to permit differential detection by in situ hybridization. Thus, elucidation of the control elements for transcription of the prosaposin locus is essential to understanding the relationship of this regulation, biological function, and the modulation of its activities in various tissues. For the current studies, we have focused on the 310-bp 5' to the transcriptional start site, since initial analysis in transgenic mice indicates that this is an important region for promoter activity in the central nervous system. The present results indicate a potential for complex regulation based upon the milieu of transcription factors present in various tissues. The current studies define an essential Sp1 binding site (Sp1D) just 5' to the transcription start site and a 5' functional Sp1/U cluster (Sp1A, -B, and -C, and an unknown factor (U)), and RORE. All of these participate in the modulation of prosaposin transcriptional activity. Furthermore, Sp1 and Sp3 interact at sites in the Sp1/U cluster to modulate prosaposin transcriptional activity. Sp1, Sp3, and Sp4 bind to the Sp1D site. Other potential binding sites in this region, i.e. AP-1 and GATA, were nonfunctional and apparently play little role in the modulation of transcriptional activity of this locus.

The most 3' Sp1 site, just 16 bp upstream from the major transcriptional start site, is essential to promoter activity. From EMSA, the Sp1, Sp3, and Sp4 members of the Sp family of transcription factors bind to this region. Although Sp1 and Sp3 are ubiquitously expressed with some temporal and spatial regulation of expression (28), Sp4 expression appears to be limited to brain and the reproductive system (29). Thus, the binding of Sp1, Sp3, and Sp4 at the Sp1D site depends on the transcription factor milieu that may determine the tissue specific expression of prosaposin. The NS20Y line used here has cholinergic properties and prosaposin exerts neurite outgrowth effects in this particular NS20Y subculture (8). Also, a high level of expression of the prosaposin gene was observed in NS20Y cells by immunofluorescence analyses.2 Thus, we selected this cell type to assess the specific effects of our constructs in nervous system tissues, since primary cultures of various neurons are not clearly adaptable to transfection assays. It appears that the NS20Y cells contain at least some complement of the endogenous transcription factors present in specific neurons in the brain and probably are not representative of all specific neuronal types throughout the brain substance. Ongoing transgenic analyses in these laboratories show that the Sp1D site is also essential to prosaposin expression in transgenic animals (30). Based upon the ubiquitous expression of Sp1 and Sp3, we would propose that the Sp1D site is responsible for basal expression of prosaposin in a variety of tissues. Thus, the basal expression provided by this Sp1 site could be modulated by varying and competitive Sp3 or Sp4 levels. The Sp1D site would provide for necessary lysosomal functions of the derived saposins on glycosphingolipid hydrolases throughout the body. This Sp1 site would require interaction with other promoter components for tissue-specific modulation of transcription and activity observed throughout development and in a variety of cellular types, particularly in the brain and reproductive system.

The Sp1A, -B, and -C; U; and RORE sites appear to have a primarily negative regulatory effects on the basal activity of Sp1D in NS20Y cells. This conclusion is based upon the findings that individual mutations of these binding sites lead to an enhanced activity of the reporter gene when the Sp1D site is functional. However, when the Sp1D site is mutated, these upstream sites have some positive effects on the reporter gene transcription and can provide a substantial level expression. Mutation of all of the sites, the 5' Sp1/U cluster, RORE, and the Sp1D, nearly obliterates activity. The negative modulatory effects on the Sp1D site of these upstream sites are supported by the relatively weak protection in DNA footprinting of the most Sp1A, -B, and -C sites and the U site. Indeed, an explanation for this relatively weak footprint is the presence of competing transcription factors Sp1 and Sp3, and potentially U, for this region leading to a less clear footprint than might be anticipated. Strong and very distinct footprints are obtained in the 5' Sp binding regions with purified Sp1 protein. The EMSA assays clearly show specific binding to sites in this Sp1/U cluster region and competition between Sp1 and Sp3. Although the Sp1C and U sites overlap, EMSA analysis indicated they have separable activities. The U site is not an MZF binding site as is evident from competition assays with cold oligonucleotides. Thus, the transcription factor binding to the U site remains unidentified. However, the mutagenesis, supershift, and competition assays support interaction of Sp1, Sp3, and U in a complex manner for the binding sites at this upstream region. The mutagenesis of individual Sp1 and the U sites within this cluster leads to increased promoter activity over the wild-type sequence. The largest increases were observed with mutagenesis of the Sp1B and -C sites in the cluster with or without U mutations. Lower promoter activity was found with two of these cluster Sp1 sites, with or without U being obliterated. These results indicate a negative interaction between the factors binding to the Sp1B or -C sites and the U site in the cluster. The increase in absolute activity between m234 and m310 shows a positive overall effect of the presence of this 5' cluster. The RORE has additive effects (~23%) on promoter activity in the context of the Sp1D site. In constructs containing the 5' Sp1/U cluster, the effects are less than expected. For example, m310mK increased promoter activity relative to wild type when RORE was mutated; i.e. this indicates a negative interaction between factors binding at RORE and the 5' Sp1/U cluster. The greater activity with m310mQ than m310mG suggests that negative interaction is primarily via the Sp1A and -B sites in the cluster, but U is not involved. Thus, it is likely that the tissue milieu of transcription factors that compete for these upstream sites could provide a variety of suppressive interactions for the Sp1D site and modulate the background activity provided by an unmodulated Sp1D site.

The RORalpha nuclear receptor is expressed primarily in neurons of the brain and provides a tempting target for the neuronal specific expression modulation of prosaposin. In particular, the recent identification of the RORalpha gene deletion in the staggerer mouse indicates the profound effects of the absence of this receptor (31). In the staggerer mouse, Purkinje cell development and migration as well as olivo-pontine neurons degenerate progressively through adulthood (32). Thus, some target sequences for RORalpha have a maintenance and, potentially, trophic effect upon these specific types of neurons during brain development. The massive destruction of neurons in the brains of the prosaposin knockout make it difficult to assess trophic effects of prosaposin deficiency in that animal model, but the staggerer mouse may provide an interesting model system for the evaluation of prosaposin trophic effects on cerebellar development and maintenance.

The mutagenesis and expression studies support a complex model of prosaposin promoter function within the first 310 bp 5' to the transcription start site. A model is proposed in Fig. 8 that indicates a basal functional activity of the 3' Sp1 site and a combination of transcription factor interactions at the more upstream sites that are primarily negative in their modulatory functions. The negative effects are principally mediated by a negative (competitive) interaction of factors binding to the Sp1/U cluster, since enhanced promoter activity is observed when any of the sites in this cluster are obliterated. RORE factors also negatively interact with this cluster, since enhanced activity of m310 is apparent when RORE is destroyed. For the Sp1/U cluster, we showed competition of Sp1 and Sp3. We would propose that such competition could be extended to Sp4 at the Sp1D site and that the occupancy of various transcription sites, depending upon the chromatin and DNA structure in the region, could interfere or interact with each other to down- or up-regulate the basal Sp1D site function. These studies have not defined factors that are clearly tissue-specific for the modulation of prosaposin function in neurons, the reproductive tract, or specific epithelial cells throughout the body. Our previous in vitro studies indicate negative regulatory elements within the first 741 bp 5' to the transcription start site and the large first intron (~15 kb) provide additional targets for tissue specificity and/or facilitator functions of prosaposin expression in more physiologic systems. However, our preliminary transgenic data (30) show that the first 310 bp 5' to the start site contains elements that promote prosaposin expression in neurons of the central nervous system and that the interaction of the factors described here must have a significant effect on the modulation of regional prosaposin expression in that organ system.


View larger version (13K):
[in this window]
[in a new window]
 
Fig. 8.   Proposed model of transcriptional regulation of the murine prosaposin locus. The binding proteins are shown below, the binding sites are shown on the line, and the interactive effects of the binding proteins are indicated above. The Sp1D site has a basal functional activity and under normal circumstances is essential for promoter activity. Sp1, Sp3, and Sp4 proteins can bind to this site independently. The factors binding to the Sp1A, -B, and -C and U and RORE interact negatively with each other. This may result from crowding of the factors or other structural effects. Sp1 and Sp3 proteins can bind to the 5' Sp1 cluster. Individually, the factors that bind to the 5' Sp1/U cluster and RORE can activate the transcription of the prosaposin gene even in the absence of Sp1D site. The occupancies of transcription factor binding sites vary among different tissues, which make this region drive tissue-preferential expression.

    FOOTNOTES

* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed: Director of Human Genetics Division, Children's Hospital Medical Center, 3333 Burnet Ave., PAV 3-52, Cincinnati, OH 45229-3039. Tel.: 513-636-7290; Fax: 513-636-7297; E-mail: GRABG0{at}CHMCC.ORG.

1 The abbreviations used are: bp, base pair(s); kb, kilobase pair(s); EMSA, electrophoretic mobility shift assay; DMEM, Dulbecco's modified Eagle's medium; RORE, ROR response element; MZF, myeloid zinc finger; O1-O4, oligonucleotides 1-4, respectively; MO1 and MO4, mutant oligonucleotides 1 and 4, respectively.

2 P. Jin, Y. Sun, and G. A. Grabowski, unpublished observation.

    REFERENCES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

  1. O'Brien, J. S., Kretz, K. A., Dewji, N., Wenger, D. A., Esch, F., and Fluharty, A. L. (1988) Science 241, 1098-1101[Medline] [Order article via Infotrieve]
  2. Gavieli-Rorman, E., and Grabowski, G. A. (1989) Genomics 5, 486-492[Medline] [Order article via Infotrieve]
  3. Nakano, T., Sandhoff, K., Stumper, J., Christomanou, H., and Suzuki, K. (1989) J. Biochem. (Tokyo) 105, 152-154[Abstract]
  4. Sandhoff, K., Harzer, K., and Furst, W. (1995) Scriver, C. R., Beaudet, A. L., and Valle, D., eds) pp. 2427-2442, McGraw-Hill Inc., New York
  5. Collard, M. W., Sylvester, S. R., Tsuruta, J. K., and Griswold, M. D. (1988) Biochemistry 27, 4557-4564[Medline] [Order article via Infotrieve]
  6. O'Brien, J. S., Carson, G. S., Seo, H. C., Hiraiwa, M., and Kishimoto, Y. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 9593-9596[Abstract/Free Full Text]
  7. O'Brien, J. S., Carson, G. S., Seo, H. C., Hiraiwa, M., Weiler, S., Tomich, J. M., Barranger, J. A., Kahn, M., Azuma, N., and Kishimoto, Y. (1995) FASEB J. 9, 681-685[Abstract/Free Full Text]
  8. Qi, X., Qin, W., Sun, Y., Kondoh, K., and Grabowski, G. A. (1996) J. Biol. Chem. 271, 6874-6880[Abstract/Free Full Text]
  9. Kotani, Y., Matsuda, S., Sakanaka, M., Kondoh, K., Ueno, S-U., and Sano, A. (1996) J. Neurochem. 66, 2019-2025[Medline] [Order article via Infotrieve]
  10. Hiraiwa, M., Soeda, S., Kishimoto, Y., and O'Brien, J. S. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 11254-11258[Abstract]
  11. Fujita, N., Suzuki, K., Vanier, M. T., Popko, B., Maeda, N., Klein, A., Henseler, M., Sandhoff, K., Nakayasu, H., and Suzuki, K. (1996) Hum. Mol. Genet. 5, 711-725[Abstract/Free Full Text]
  12. Holtschmidt, H., Sandhoff, K., Kwon, H. Y., Harzer, K., Nakano, T., and Suzuki, K. (1991) J. Biol. Chem. 266, 7556-7560[Abstract/Free Full Text]
  13. Gavrieli-Rorman, E., Scheinker, V., and Grabowski, G. A. (1992) Genomics 13, 312-318[Medline] [Order article via Infotrieve]
  14. Sun, Y., Witte, D. P., and Grabowski, G. A. (1994) Am. J. Pathol. 145, 1390-1398[Abstract]
  15. Sprecher-Levy, H., Orr-Urtreger, A., Lonai, P., and Horowitz, M. (1993) Cell. Mol. Biol. 39, 287-299
  16. Sun, Y., Jin, P., and Grabowski, G. A. (1997) DNA Cell Biol. 16, 23-34[Medline] [Order article via Infotrieve]
  17. Schreiber, E., Mattias, P., Muller, M. M., and Schaffner, W. (1989) Nucleic Acids Res. 17, 6419[Medline] [Order article via Infotrieve]
  18. Bradford, M. M. (1976) Anal. Biochem. 72, 248-254[CrossRef][Medline] [Order article via Infotrieve]
  19. Bohinski, R. J., Di Lauro, R., and Whitsett, J. A. (1994) Mol. Cell. Biol. 14, 5671-5681[Abstract]
  20. Maxam, A., and Gilbert, W. (1980) Methods Enzymol. 65, 499-560[Medline] [Order article via Infotrieve]
  21. Giguere, V., Tini, M., Flock, G., Ong, E., Evans, R. M., and Otulakowski, G. (1994) Genes Dev. 8, 538-553[Abstract]
  22. Giguere, V., McBroom, L. D. B., and Flock, G. (1995) Mol. Cell. Biol. 15, 2517-2526[Abstract]
  23. Hagen, G., Muller, S., Beato, M., and Suske, G. (1992) Nucleic Acids Res. 20, 5519-5525[Abstract]
  24. Kinsley, C., and Winoto, A. (1992) Mol. Cell. Biol. 12, 4251-4261[Abstract]
  25. Morris, J. F., Hromas, R., and Rauscher, F. J., III (1994) Mol. Cell. Biol. 14, 1786-1795[Abstract]
  26. Du, H., Witte, D. P., and Grabowski, G. A. (1996) J. Lipid Res. 37, 937-949[Abstract]
  27. Ponce, E., Witte, D. P., Hirschhorn, R., and Grabowski, G. A. (1997) Am. J. Hum Genet. 61, 180 (abstr.)
  28. Saffer, J. D., Jackson, S. P., and Annarella, M. B. (1991) Mol. Cell. Biol. 11, 2189-2199[Medline] [Order article via Infotrieve]
  29. Supp, D. M., Witte, D. P., Branford, W. W., Smith, E. P., and Potter, S. S. (1996) Dev. Biol. 176, 284-299[CrossRef][Medline] [Order article via Infotrieve]
  30. Sun, Y., Jin, P., and Grabowski, G. A. (1996) Am. J. Hum. Genet. 59, 160 (abstr.)
  31. Hamilton, B. A., Frankel, W. N., Kerrebrock, A. W., Hawkins, T. L., FitzHugh, W., Kusumi, K., Russell, L. B., Mueller, K. L, Berkel, V. V., Birren, B., Kruglyak, L., and Lander, E. (1996) Nature 379, 736-739[CrossRef][Medline] [Order article via Infotrieve]
  32. Hadj-Sahraoui, N., Frederic, F., Zanjani, H., Herrup, K., Delhaye-Bouchaud, N., and Mariani, J. (1997) Brain Res. Dev. Brain Res. 98, 1-8[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.